Literature DB >> 8778195

Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma.

J P Bronowicki1, K Boudjema, L Chone, G Nisand, C Bazin, F Pflumio, G Uhl, J J Wenger, D Jaeck, P Boissel, M A Bigard, P Gaucher, D Vetter, M Doffoel.   

Abstract

BACKGROUND/AIMS: Resection and liver transplantation are currently considered as the most useful treatments for hepatocellular carcinoma. However, transcatheter oily chemoembolization may be favourably compared with these two surgical treatments in patients with anatomically operable tumors.
METHODS: Between 1985 and 1991, 122 patients with an Okuda stage I tumor were hospitalized in two French hospitals. Among these patients, 33 remained untreated, 42 were treated by transcatheter oily chemoembolization, 30 by resection and 17 by liver transplantation. The four groups were closely comparable except for age, the patients in the two surgical groups being significantly younger. Moreover, the frequency of pTNM II tumor was significantly higher in the resection group.
RESULTS: The 5-year probability of survival was close to 45% in each of the three treated groups and was significantly higher than in the untreated group (0% at 4 years, p < 0.0001). The probability of cancer recurrence and/or metastatic dissemination was lower after transcatheter oily chemoembolization than after surgery.
CONCLUSION: Thus, transcatheter oily chemoembolization seems comparable at 5 years with resection or transplantation for the treatment of resectable hepatocellular carcinoma.

Entities:  

Mesh:

Year:  1996        PMID: 8778195     DOI: 10.1016/s0168-8278(96)80007-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.

Authors:  Mikio Tezuka; Keiji Hayashi; Yoichi Okada; Tetsuya Irie; Hiroyasu Ina
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

Review 2.  [1997 gastroenterology update--II].

Authors:  W Fischbach; V Gross; J Schölmerich; C Ell; P Layer; W E Fleig
Journal:  Med Klin (Munich)       Date:  1998-03-15

3.  Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization.

Authors:  Seung Joon Choi; Jonghoon Kim; Jongbum Seo; Hyung Sik Kim; Jong-min Lee; Hyunjin Park
Journal:  Eur Radiol       Date:  2015-05-20       Impact factor: 5.315

4.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

5.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

6.  Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.

Authors:  Mike-S-L Liem; Ronnie-T-P Poon; Chung-Mau Lo; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 7.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 8.  Management of hepatocellular carcinoma.

Authors:  Janice N Cormier; K Tyson Thomas; Ravi S Chari; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

Review 9.  Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

Authors:  Gino Boily; Jean-Pierre Villeneuve; Luc Lacoursière; Prosanto Chaudhury; Félix Couture; Jean-François Ouellet; Réal Lapointe; Stéphanie Goulet; Normand Gervais
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

10.  Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization.

Authors:  Young-Joo Jin; Young-Hwa Chung; Jeong A Kim; Wonhyeong Park; Don Lee; Ju Hyun Shim; Danbi Lee; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Yung Sang Lee; Pyo Nyun Kim; Kyu Bo Sung
Journal:  Dig Dis Sci       Date:  2013-01-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.